# Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

> **NCT04334330** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 34 (estimated)

## Conditions studied

- Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant

## Key facts

- **NCT ID:** NCT04334330
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-04
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04334330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04334330, "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04334330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*